IGF-II TREATMENT PREVENTS THE OXIDATIVE DAMAGE DERIVED BY MPP+/MPTP ADMINISTRATION IN A CELLULAR AND ANIMAL MODEL OF PARKINSON’S DISEASE

• Pablo Zamorano-González,
• Nadia Valverde,
• Silvia Claros Gil,
• Manuel Víctor López-González,
• Silvana Yanina Romero-Zerbo,
• Estrella Lara,
• Federica Boraldi,
• José Pavia,
• María García-Fernández,
• Belén Gago,
• Elisa Martín-Montañez

Affiliations

Pablo Zamorano-González

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Nadia Valverde

UNIVERSITY OF MALAGA (FACULTY OF MEDICINE), Department Of Pharmacology And Paediatrics, Málaga, Spain

Silvia Claros Gil

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Manuel Víctor López-González

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Silvana Yanina Romero-Zerbo

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Estrella Lara

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Federica Boraldi

UNIVERSITY OF MODENA E REGGIO EMILIA, Department Of Life Sciences, MODENA, Italy

José Pavia

UNIVERSITY OF MALAGA (FACULTY OF MEDICINE), Department Of Pharmacology And Paediatrics, Málaga, Spain

María García-Fernández

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Belén Gago

UNIVERSITY OF MALAGA, Department Of Human Physiology (faculty Of Medicine), MALAGA, Spain

Elisa Martín-Montañez

UNIVERSITY OF MALAGA (FACULTY OF MEDICINE), Department Of Pharmacology And Paediatrics, Málaga, Spain